Evidence map›Paper›PMID 42730763›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2026

Prognostic value and diagnostic performance of nectin-4-targeted [

Ye Li, Yuyun Sun, Li Sun, Dongliang Wang, Xiaoyu Pan, Xiaoping Xu, Shaoli Song

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ye LiDepartment of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, China.
Yuyun SunDepartment of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, China.
Li SunDepartment of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, China.
Dongliang WangDepartment of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, China.
Xiaoyu PanDepartment of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, China.
Xiaoping XuDepartment of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, China. xxp0012@ustc.edu.
Shaoli SongDepartment of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, China. shaoli-song@163.com.ORCID http://orcid.org/0000-0003-2544-7522

Funding

Key Program of National Natural Science Foundation of China U23A20465National Natural Science Foundation of China 12275057National Natural Science Foundation of China 82272035Nuclear Technology R&D Program HNKFHBZ202319Science and Technology Commission of Shanghai Municipality 23DZ2291400Shanghai Collaborative Innovation Project HCXBCY-2024-001Shanghai Oriental Talents Program Youth Project SSF828085
6 · The paper itself

Abstract

purposeNectin-4 has emerged as an attractive diagnostic and therapeutic target in a wide range of malignancies. Herein, we aimed to evaluate the clinical utility of a novel Nectin-4-targeted radiotracer, [

methods40 patients with recurrent or metastatic TNBC who underwent [

results[

conclusion[

Indexed as

Diagnostic performanceNectin-4PET/CTSurvival outcomeTriple negative breast cancer

Identifiers

PMID42730763

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.